The FDA has approved Johnson & Johnson’s Icotyde (icotrokinra), the first oral IL-23 inhibitor for moderate-to-severe plaque psoriasis in patients 12 and older. With peak sales projected above $5 billion, this will become one of the most commonly prescribed medications in dermatology — and payer coverage decisions will follow quickly.
Why This Matters for Dermatology Practices
Icotyde is significant because it’s oral, not injectable. Unlike existing IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) that require in-office or self-administered injections, Icotyde is taken by mouth. This changes the billing model entirely:
- No injection administration fees — patients take it at home
- Pharmacy benefit vs. medical benefit — most oral medications are covered under pharmacy, not medical
- Different prior auth pathways — pharmacy PAs go through PBMs, not medical management
- No buy-and-bill revenue — unlike infused biologics, you don’t purchase and bill for the drug
Billing and Coding Considerations
Prescription Coding
As an oral medication, Icotyde will be billed through the pharmacy benefit using NDC codes, not HCPCS J-codes. The prescribing visit itself is billed as a standard E/M encounter.
Prior Authorization
Expect aggressive step therapy requirements, especially from PBMs managing biologics spend. Payers will likely require documented failure of at least one traditional systemic therapy (methotrexate, cyclosporine) and possibly one injectable biologic before approving Icotyde.
Payer coverage decisions for Icotyde will likely emerge within the next 1-2 quarters. Monitor your top 5 payers’ formulary updates and prior auth criteria as they become available.
Impact on Your Practice
- Patient demand will be high — an oral option for psoriasis is what many patients have been waiting for
- Prior auth volume will increase — every Icotyde prescription will likely require PA initially
- E/M documentation matters — document failed prior therapies clearly to support PA
- Revenue model shifts — if patients move from in-office injectable biologics to oral Icotyde, you lose the administration fee revenue
Key Takeaways
- Icotyde is the first oral IL-23 inhibitor — game-changer for psoriasis treatment
- Billed through pharmacy benefit (NDC), not medical benefit (J-codes)
- Expect aggressive step therapy and prior auth requirements
- Document failed prior therapies thoroughly to support PA approvals
- Monitor your top payers’ formulary decisions over the next 2 quarters
- Assess revenue impact if patients shift from injectable to oral biologics